EXACT Therapeutics AS ("EXACT-Tx') held its Annual General Meeting on June 1st
2021 at 1300hrs CET. According to the record included as Appendix 1, 16,257,225
shares of a total of 29,967,750 issued shares and votes, corresponding to 54.25%
of the total number of voting shares in the Company, were represented at the
general meeting. 

All proposed resolutions were approved. 

Please find enclosed the minutes of the meeting including appendices.

For further information, please contact:

Dr Rafiq Hasan, CEO
rafiq@exact-tx.com

About EXACT-Tx
EXACT-Tx is a clinical stage Norwegian biotech company developing a technology
platform for targeted therapeutic enhancement - Acoustic Cluster Therapy (ACT®).
ACT® sonoporation is a unique approach to ultrasound-mediated, targeted drug
enhancement - with the potential to significantly amplify the clinical utility
of a wide range of therapeutic agents across a multitude of indications
including within oncology (chemotherapy, immunotherapy), infectious diseases,
and neurological conditions. www.exact-tx.com